Clinical Trial Details
— Status: Completed
Administrative data
NCT number |
NCT05545644 |
Other study ID # |
R34AA023304 |
Secondary ID |
|
Status |
Completed |
Phase |
N/A
|
First received |
|
Last updated |
|
Start date |
April 1, 2015 |
Est. completion date |
May 30, 2019 |
Study information
Verified date |
April 2024 |
Source |
University of New Mexico |
Contact |
n/a |
Is FDA regulated |
No |
Health authority |
|
Study type |
Interventional
|
Clinical Trial Summary
Family-involved treatments for alcohol use disorders (AUDs) hold considerable promise to
improve engagement and compliance with treatment and improve treatment outcomes. Currently,
however, these treatments are time-intensive and difficult to learn and to integrate with
on-going clinical treatment. Consistent with the general trend toward briefer treatments, we
propose to develop a brief, 3-session, family-involved treatment that can be incorporated
into a variety of other AUD treatment modalities. If successful, the treatment may increase
the efficiency and effectiveness of AUD treatment.
Description:
The overall aim of this treatment development study is to develop an efficacious, brief,
family-involved treatment that can be used flexibly in on-going alcohol treatment settings to
advance the dissemination of evidence-based treatment. The treatment to be developed and
tested in this grant, "B-FIT" (Brief Family-Involved Treatment), builds on the PI's earlier
National Institute on Alcohol Abuse and Alcoholism (NIAAA)-supported efficacy trials and
studies of mechanisms of change in Alcohol Behavioral Couple Therapy (ABCT) and is designed
as an add-on to community-based substance abuse treatment-as-usual (TAU). B-FIT uses family
involvement to enhance patient treatment adherence and outcomes by improving family
functioning and increasing family-provided incentives for treatment adherence and abstinence.
Study aims are carefully sequenced to develop the B-FIT approach and to judge its merits
through a rigorous set of fidelity analyses, a small-scale clinical trial, and prospective
tests of potential active ingredients, mediators, and moderators of treatment response.
Specific are to: (1) modify ABCT to make it (a) appropriate for any concerned family member,
(b) shorter, (c) focused on key mechanisms of change, (d) appropriate for use as part of an
on-going alcohol treatment program, and (e) more efficacious by incorporating behavioral
contracting procedures; (2) conduct a small-scale clinical trial of B-FIT; and (3) finalize
materials for a larger-scale RCT. To accomplish study aims, a stage 1A successive cohort
treatment development approach followed by a stage 1B small randomized clinical trial (RCT)
will be completed. In the 1A stage, key interventions in B-FIT will be identified and
integrated into the preliminary version of the treatment manual. Then, in the 1B stage B-FIT
will be tested in an RCT to determine feasibility and preliminary efficacy. The project
includes six phases: (1) focus groups with service providers, patients, and concerned family
members (CFMs) of patients to obtain feedback about the B-FIT content and materials; (2)
modification of the B-FIT protocol in response to the focus group feedback; (3) clinician
training in the B-FIT protocol followed by pilot testing with six patients and their CFMs.
Each clinician, patient, and CFM will be debriefed after the treatment to assess the B-FIT
intervention. (4) Further modifications to the B-FIT materials in response to feedback from
the pilot study as well as a second set of focus groups used to obtain feedback on the B-FIT
written materials in terms of readability, relevance, and ease of use. (5) Structured
didactic and experiential training for clinicians on the B-FIT treatment. (6) A small-scale,
randomized clinical trial of TAU versus B-FIT + TAU will be conducted with 60 patients and
their CFMs to (a) test the feasibility of B-FIT and impact on patient treatment retention,
(b) obtain effect size estimates for pre-post changes in drinking, CFM, and family
functioning; (c) assess therapist fidelity; (d) measure hypothesized active ingredients in
the treatment; and (e) conduct initial moderator analyses. In parallel with phases 1-5 all
measures and study procedures will be finalized. Three-month follow-up data will be collected
as part of the clinical trial.